Clinical trial
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute…
NCT00395772 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00395772 |
|---|---|
| Title | Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis |
| Official title | Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation. |
| Lead sponsor | Bayer, Industry |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Venous Thromboembolism |
| Intervention type | Drug |
| Interventions | Xarelto (Rivaroxaban, BAY59-7939), (LMW) Heparin + Vitamin K Antagonist |
| Enrollment | 543 |
| Start date | Dec 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | Nov 3, 2006 |
| Last update posted | Oct 28, 2014 |
| Countries | Australia, Brazil, Canada, Czechia, Denmark, France, Israel, Italy, Netherlands, Poland, South Africa, Sweden and 1 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: